Providing high-quality healthcare services to even more people

As the leading generic drug company, we strive to provide a stable supply of high-quality generic drugs and support the healthy lives of people. We are also taking on the challenge of evolving into a general healthcare company by developing new businesses.

Social issues

Rising medical expenses

Medical expenses

¥45.0 trillion (FY2021)

The hyper-aging society

Percentage of Japanese population aged 65 or older

29.1%

(September 2023)

Need for affordable

and safe drugs Target share (volume) of generic drugs for all prefectures

80% or more

(through March 31, 2029)

Supply shortage of drugs

Drugs whose shipments have been suspended or limited

23% of all drugs (as of April 2024)

Increasing interest in QOL

Difference between average life expectancy and healthy life expectancy

Women:

Men:

9 years 12 years

Management capital (Input)

Financial capital

R&I credit rating

A–

Manufactured capital

Production capacity

18.5 billion tablets/year

Number of production facilities

8

Human capital*1

Employees

3.037

Of which are in Manufacturing Division

2.097

Of which are in R&D Division

Intellectual capital

Patents owned

53

Social and relationship capital Strongest brand

in generic drug industry*2

(as of March 31, 2024)

Sawai Group Vision 2030

The World We Want

A world where more people can receive healthcare services and live a full life with peace of mind among society

Our Ideal

A company with a strong presence that continues to contribute to people's health by providing a multifaceted mix of products and services that meet individual needs based on scientific evidence

Business activities

Generic drug business



New businesses

Digital

medical

devices

business

development

- Formulation technology capabilities based on human resources with expertise in API properties
- and formulation technology Ability to undertake research and analysis of original drug patents

Procurement

- Strong new product API research and procurement
- abilities • Selection and procurement of raw materials with primary emphasis on

quality and safety

as new treatment methods for acute-phase

personal health record (PHR) management

Material issues leading to value creation

Improving healthcare access / Contributing to healthcare financing /

Contributing to extension of healthy life expectancy / Developing talent

and reliability assurance Manufacturing know-how

Production

- for high-mix, low-volume Stringent quality
- management • Establishment of a trusted corporate foundation

Health food

business

New drugs

business

Sales and

- market
- Provision of accurate information

By expanding our business to the pre-symptomatic

products that support longer healthy lives.

technology capabilities, we will provide new

By making the most of our formulation

Material issues as the foundation of sustainable growth

Environmentally friendly business / Work styles, motivation,

and respect for human rights / Corporate governance

• Extensive product lineup

Japan generic drug business

Production volume 15.9 billion tablets

Business

results (Output)

¥176.9 billion

Operating profit

ROIC

¥18.6 billion

6.6% 4.8%

ROE

Revenue

New products 10 products

Patent applications 30

New businesses

Obtained marketing and manufacturing approval

for the non-invasive neuromodulation device Relivion®

(first in Japan)

Launched phase 3 clinical trial for NASH

(FY2023 results)

Value provided to society (Outcome)

Improving healthcare access

Sales volume

15.7 billion tablets

Contributing to healthcare financing

Amount of reduction

¥293.9 billion

Contributing to extension of healthy life expectancy

Personal health record (PHR) Used by more than

1,300 medical institutions

Developing talent

Employee education and training expenses

¥92.23 million

- *1 Total for Sawai Group Holdings, Sawai Pharmaceutical, Medisa Shinyaku, Kaken Shoyaku, and Trust Pharmatech
- *2 14th consecutive year ranked top in approval rating among generic drug companies favored by pharmacists (Research by Nikkei Drug Information)
- *3 Non-alcoholic steatohepatitis

Sawai Group Holdings Integrated Report 2024 Sawai Group Holdings Integrated Report 2024 16